Showing 1751-1760 of 4064 results for "".
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-ohcm-the-emerging-role-of-cardiac-myosin-inhibitors/33176/Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin InhibitorsReal-World Ready: Practical Tips for Community Oncologists
https://reachmd.com/programs/cme/real-world-ready-practical-tips-for-community-oncologists/36572/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityClinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://reachmd.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
https://reachmd.com/programs/cme/the-neverending-journey-a-66-year-old-patient-who-has-undergone-several-rounds-of-tea-tree-oilbased-treatment/56707/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
https://reachmd.com/programs/cme/return-and-revisit-a-38-year-old-patient-returns-for-follow-up-after-lotilaner-treatment/56709/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
https://reachmd.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.RF Microneedling Safety: Reframing the Conversation with Leading Experts Ch. 4
https://reachmd.com/programs/modern-aesthetics/rf-microneedling-safety-reframing-the-conversation-with-leading-experts-ch-4/56968/Konika Patel Schallen, MD, moderates as five aesthetic physicians discuss safety and regulatory considerations involving radiofrequency (RF) microneedling procedures, and how the safety measures built into Candela’s Matrix system differentiate it from anything else on the market. For more informatiHigher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines
https://reachmd.com/programs/project-oncology/higher-risk-lowered-age-new-colorectal-cancer-screening-guidelines/10309/The American Cancer Society responds to the rise of colorectal cancer in younger generations with the unveiling of new screening guidelines.Daily Contact Lenses for New and Existing Patients
https://reachmd.com/programs/empower/daily-contact-lenses-for-new-and-existing-patients/56896/A high-concept guide on getting patients into dailies, switching patients to a different daily, and ensuring that patients are equipped for success.Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
https://reachmd.com/programs/neurofrontiers/multiplex-proteomic-biomarkers-ms/54239/Multiplex proteomic biomarker panels are redefining how we understand and monitor multiple sclerosis (MS) by capturing interconnected pathways in a single sample. Hear from Dr. Raphael Schneider as he explores how these tools could inform prognosis, risk stratification, and clinical trial design, wh